Clinical trials: Atherosclerosis, Endothelial Dysfunction
Arthritis, Rheumatoid, Atherosclerosis
Does Sildenafil Improve Endothelial Dysfunction in Rheumatoid Arthritis?
The purpose of this study is to determine whether sildenafil improves parameters of vascular function and blood markers involved in development of heart disease in patients with rheumatoid arthritis.
- Trial name
- NCT02908490
- Testing
- Sildenafil
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Kimberly Liang
Stable Angina Pectoris, Atherosclerosis
Effect of Molsidomine on the Endothelial (Internal Layer of Blood Vessels) Dysfunction in Patients With Angina Pectoris
Molsidomine used as an add-on treatment on standard care therapy should be superior to placebo used also as an add-on treatment on standard care therapy on improving the endothelial function (endothelium score measured by…
- Trial name
- MEDCOR (NCT01363661)
- Testing
- Coruno
- Where
- Belgium
- Volunteers
- 165 people
- Sponsor
- Therabel Pharma SA/NV
Endothelial Dysfunction
The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis
We will study the hypothesis that long-term Tekturna treatment will improve endothelial function and the production and function of endothelial progenitor cells (EPCs) in patients with early atherosclerosis.
- Trial name
- NCT01067326
- Testing
- Aliskiren
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Mayo Clinic
Coronary Artery Disease, Endothelial Dysfunction
Darusentan Effect on PET Uptake Heterogeneity
The primary objective of this study is to test the hypothesis that myocardial perfusion heterogeneity, quantified by Markovian Homogeneity analysis of cardiac PET perfusion images, will improve in a quantitative manner after…
- Trial name
- Darusentan (NCT00738049)
- Testing
- darusentan 100 mg
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- K.Lance Gould
Peripheral Arterial Disease
Clinical Utility of Endothelial Dysfunction in PAD
This study will seek to determine whether non-invasive measures of endothelial function have utility as surrogate markers of cardiovascular risk in patients with peripheral arterial disease undergoing vascular surgery.
- Trial name
- NCT00491751
- Testing
- atorvastatin, ascorbic acid
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- Boston University
Type 2 Diabetes, Peripheral Arterial Disease
Liraglutide and Peripheral Artery Disease
STARDUST is an open-label, two-arm randomized controlled trial, aimed at evaluating the effects of liraglutide on peripheral perfusion, as compared with the aggressive treatment of cardio-metabolic risk factors, in people with…
- Trial name
- STARDUST (NCT04881110)
- Testing
- Liraglutide, Control
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- University of Campania Luigi Vanvitelli
HIV, Vascular Diseases
Pentoxifylline and Combination Antiretroviral Therapy to Improve Blood Vessel Function in HIV-Infected People
People infected with HIV have a greater risk of developing cardiovascular disease than people not infected with HIV. This may be due to increased inflammation in the blood vessels.
- Conditions
- HIV, Vascular Diseases, Cardiovascular Diseases, Atherosclerosis
- Trial name
- NCT00864916
- Testing
- Combination antiretroviral therapy (cART), Pentoxifylline
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Indiana University
Coronary Artery Disease, Atherosclerosis
Rilonacept to Improve Artery Function in Patients With Atherosclerosis
This study will determine whether an experimental drug called Rilonacept can improve artery function in patients with atherosclerosis, a disease in which fatty deposits in arteries cause the vessels to stiffen, impeding blood…
- Conditions
- Coronary Artery Disease, Atherosclerosis, Inflammation, Endothelial Dysfunction
- Trial name
- NCT00417417
- Testing
- Rilonacept
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Atherosclerotic Vascular Disease, Type2 Diabetes
The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular Disease
Experimental models have linked lipid lowering therapies with systemic inflammation; however, relatively little is known about this network in clinical populations and specifically how it changes with PCSK9 inhibition.
- Conditions
- Atherosclerotic Vascular Disease, Type2 Diabetes, Microvascular Dysfunction
- Trial name
- NCT03829046
- Testing
- Evolocumab
- Where
- 2 sites in United States, Canada
- Volunteers
- 41 people
- Sponsor
- Robert Rosenson
Carotid Artery Diseases, Atherosclerosis
Effect of Valsartan on Carotid Artery Disease
The EFFERVESCENT trial is designed to evaluate the effects of a specific ARB, called valsartan, on atherosclerosis. The investigators want to know if treatment with valsartan will increase the blood levels of markers responsible…
- Trial name
- NCT00208767
- Testing
- Valsartan
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Emory University
Obesity, Atherosclerosis
Endothelial Dysfunction in Obese Children
The purpose of this study is to objectify the effect of diet and exercise on early markers of atherosclerosis in obese children.
- Trial name
- EDOC (NCT01461226)
- Testing
- Exercise training, Usual care
- Where
- 3 sites in Belgium
- Volunteers
- 61 people
- Sponsor
- University Hospital, Antwerp
Intermittent Claudication
A Phase 2 Study of the Effects of Sapropterin Dihydrochloride on Symptomatic Peripheral Arterial Disease
The purpose of this study is to evaluate whether sapropterin dihydrochloride is safe and effective in the treatment of intermittent claudication (IC) caused by peripheral arterial disease (PAD).
- Trial name
- NCT00403494
- Testing
- Sapropterin Dihydrochloride
- Where
- 20 sites in United States, Argentina
- Volunteers
- 190 people
- Sponsor
- BioMarin Pharmaceutical
Endothelial Dysfunction
Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Progenitor Cells and Coronary Atherosclerosis in Humans
AIM III is a prospective, randomized, double-blinded, placebo controlled trial. The study is directly connected to IRB 08-008161 as a specific aim of the National Institute of Health (NIH) grant.
- Trial name
- NCT01067339
- Testing
- darapladib
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Mayo Clinic
Estrogen Deficiency, Cardiovascular Disease (CVD)
Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women
The purpose of this study is to determine whether young women with functional hypothalamic amenorrhea (premenopausal HypoE) is associated with risk factors for pre-clinical cardiovascular disease (CVD).
- Conditions
- Estrogen Deficiency, Cardiovascular Disease (CVD), Functional Hypothalamic Amenorrhea, Endothelial Dysfunction
- Trial name
- NCT03018366
- Testing
- 17beta Estradiol, Progesterone
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Cedars-Sinai Medical Center